U.S. markets open in 6 hours 37 minutes

Rani Therapeutics Holdings, Inc. (RANI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
18.75-0.66 (-3.40%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close19.41
Bid0.00 x 1200
Ask0.00 x 900
Day's Range18.75 - 20.53
52 Week Range9.24 - 29.40
Avg. Volume457,682
Market Cap369.649M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Rani Therapeutics Holdings, Inc
    Analyst Report: AbbVie Inc.AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • GlobeNewswire

    Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update

    - IPO in July 2021 raised $84.3 million in gross proceeds -- Talat Imran Appointed Chief Executive Officer -- Enhanced leadership team with key management and board of directors’ appointments - SAN JOSE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the second quarter ended June 30, 2021 and provided

  • GlobeNewswire

    Rani Therapeutics Announces Appointment of Eric Groen as General Counsel

    SAN JOSE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the appointment of Eric Groen as General Counsel. Mr. Groen has more than 25 years of experience managing legal matters in corporate and private practice. “Eric is an accomplished executive whose legal expertise and

  • Benzinga

    Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA

    Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ: RXST), an ophthalmology-focused MedTech company, went public in late July. Here's what BofA Securities has to say about the newly listed stocks. The Healthcare Analysts: BofA Securities analyst Geoff Meacham initiated coverage of Rani with a Buy rating and $23 price target. Bob Hopkins from BofA initiated coverage of RxSight with a Bu